Norstella and Citeline merge to create $5bn pharma tech firm

Norstella, an umbrella company, has completed its merger with pharmaceutical intelligence company Citeline, which was first announced last June.
Citeline provides intelligence, data and software for clinical trials, development and regulatory compliance. It will now join four other companies under Norstella: pharma intelligence unit Evaluate, market access specialist MMIT, healthcare data analytics software provider Panalgo and market access consultancy The Dedham Group.
As a result of the completion of the merger, Norstella has become a $5bn group with over 1,500 employees across the five branches. Its objective is to guide life sciences companies through the drug development process so patients can access therapies more quickly.
According to the company, it can advise on areas such as “revealing an unanticipated positive clinical outcome or quantifying the consequence of a delayed therapy to market”, while also helping drug developers handle and apply large amounts of real-world data effectively, and communicate the clinical efficacy of a new therapy.
Norstella chief executive Mike Gallup stated: “We believe that patient access starts with identifying unmet needs and doesn’t end until a patient has a therapy in hand. As the industry moves toward highly targeted therapies focused on smaller patient populations, our clients need solutions that provide actionable answers to critical business questions to help bring drugs to market quicker – ultimately helping patients receive treatment sooner.”